• Overview
• IO360˚ Recap
• Who Should Attend
• Agenda
• Download Agenda
• Program Advisors
• Speaking Faculty
• 2020 Sponsors / Exhibitors
• Sponsorship / Exhibit Opportunities
• 2019 Executive Sponsor Interviews
• 2019 Partners / Media
• Venue Information
• Event Blog
• Testimonials
• 2019 Speaker Presentations
• Photo Gallery
• Sign up for Updates

Overview

IO360˚ convened stakeholders spanning the science and business communities to report on data-driven advancements in immuno-oncology to fight a wider range of cancers.

---

Immuno-Oncology 360° delivered three key benefits:

1. Access to KOLs driving the science
2. Partnership opportunities with all stakeholders in Immuno-Oncology
3. Presentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology

Immuno-Oncology 360° provided 10 plenary sessions over the course of 3 days addressing:

Discovery / Preclinical Science Translational Science & Biomarkers Clinical Data Developments Clinical Operations Imaging Aspects

Cell Therapy Emerging Technologies Business Aspects Financial & Commercial Implications Trends in the Field

 

2019 Featured Speakers

We welcomed Dr Andrew Baum, Citi as part of the 2019 lead advisory committee. Guided by Dr Andrew Baum, along with Dr Axel Hoos, GSK and Dr James Gulley, NCI, the 5th annual Immuno-Oncology 360° program included more than 80 speakers and over 60 talks.

---

---

Dr David Lebwohl, Novartis discussed Learnings from Kymriah, the 1st CAR-T therapy approved by the FDA, from pivotal trials through commercialization.

Dr Andrew Baum, Citi addressed the Future Value Generation in IO at the 2018 IO360° program.

Dr Andy Lee and his entire Merck operations team walked the audience through the Building Blocks of IO trials in a new plenary session for the 2018 IO360° program.

 

If you are interested in participating in the 6th Annual Immuno-Oncology 360° 2020 program, please contact us at service@tcfllc.org. Thank you.

Sincerely,​

Kate Woda Conference Director	Valerie Bowling Executive Director
Meredith Sands Executive Director, Business Development	Geeta Bachani Business Development Manager
Elizabeth Bard Business Development Manager	Meg Gould Conference Planner
Terri Sobol Business Development Manager	Bre Bugbee Marketing Associate Manager

---

Testimonials

• "By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there’s quite a lot of folks participating who are not traditionally talking to one another on a daily basis."

  - Roy Baynes, MD, PhD, Merck

• "I really enjoyed it and connecting with some really interesting and inspiring people with whom I'm sure this is just the beginning of long standing interactions."

  - Jacqueline Karmel, Roche

• "Thank you again for the amazing invitation, it was truly my pleasure to be able to participate in the excellent event you organized."

  - Christine Ward, BMS

• "IO360° was one of the best immuno-oncology meetings I’ve been to. Kudos! Great speakers and great dialogue!"

  - Jim Mansfield, PerkinElmer

• "Congratulations again on the excellent program for the Immuno-Oncology 360° meeting. It was truly well coordinated and the topics were fantastic!"

  - Gilson Baia, PhD, Champions Oncology

• "Really good, well-rounded and novel content. Congratulations on filling the house beyond capacity and for securing such an impressive speaking faculty."

  - Eileen Daniels, Nektar Therapeutics

• "Thank you for a great conference!"

  - Elena Spanjaard, Pfizer

• "Your team did a wonderful job in putting together an interesting and relevant program."

  - Lew Bender, Intensity Therapeutics

• "It was a great conference and I was happy to be a part of it."

  - Anna Pavlick, DO, MD, NYU Cancer Center